Results 31 to 40 of about 2,782 (157)

Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes

JCEM Case Reports, 2023
Abstract Type 1 diabetes mellitus (T1DM) with obesity is increasingly common, prompting effective clinical interventions to induce weight loss in this population. We present 3 patients with T1DM and obesity prescribed a glucagon-like peptide 1 receptor agonist (GLP-1RA) and pramlintide.
Gunther Wong, Erica M Garner, Gitanjali Srivastava   +2 more
openaire   +2 more sources

Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics

Acta Pharmaceutica Sinica B, 2022
Diabetes mellitus is a major health problem with increasing prevalence at a global level. The discovery of insulin in the early 1900s represented a major breakthrough in diabetes management, with further milestones being subsequently achieved with the ...
Carlos Bendicho-Lavilla, Iria Seoane-Viaño, Francisco J. Otero-Espinar, Asteria Luzardo-Álvarez   +3 more
doaj   +1 more source

Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016Plain-language summary

Kidney Medicine, 2021
Background: Information regarding the use of glucose-lowering medications in patients with chronic kidney disease (CKD) is limited. Study Design: Retrospective cohort study.
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
doaj   +1 more source

A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model [PDF]

Osteoarthritis and Cartilage, 2019
Pain and disability are the main clinical manifestations of osteoarthritis, for which only symptomatic therapies are available. Hence, there is a need for therapies that can simultaneously alter disease progression and provide pain relief. KBP is a dual amylin- and calcitonin-receptor agonist with antiresorptive and chondroprotective properties.
A, Katri, A, Dąbrowska, H, Löfvall, M A, Karsdal, K V, Andreassen, C S, Thudium, K, Henriksen   +6 more
openaire   +2 more sources

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source

Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1/2 dorsal root ganglia

The Journal of Headache and Pain
Background The upper cervical dorsal root ganglia (DRG) are important for the transmission of sensory information associated with the back of the head and neck, contributing to head pain.
Tayla A. Rees, Zoe Tasma, Michael L. Garelja, Simon J. O’Carroll, Christopher S. Walker, Debbie L. Hay   +5 more
doaj   +1 more source

Trends in Diagnosing Obesity: The CALOR Study

Obesity, EarlyView.
Data from the CALOR study suggest that in people with elevated BMI in the US and Japan, there is underdiagnosis of obesity and a high prevalence of diseases interrelated to obesity. ABSTRACT Objective This study aimed to describe characteristics of people with elevated BMI by presence versus absence of obesity diagnosis and trends over time.
Deborah B. Horn, Eva Lesén, Christen M. Gray, Magnus Bjursell, Hironori Waki   +4 more
wiley   +1 more source

The dual amylin‐ and calcitonin‐receptor agonist KBP‐042 increases insulin sensitivity and induces weight loss in rats with obesity [PDF]

Obesity, 2016
ObjectiveIn this study, KBP‐042, a dual amylin‐ and calcitonin‐receptor agonist, was investigated as a treatment of obesity and insulin resistance in five different doses (0.625 µg/kg–10 µg/kg) compared with saline‐treated and pair‐fed controls.MethodsRats with obesity received daily s.c.
Hjuler, Sara Toftegaard, Gydesen, Sofie, Andreassen, Kim Vietz, Pedersen, Steffen Lund Kjær, Hellgren, Lars I., Karsdal, Morten Asser, Henriksen, Kim   +6 more
openaire   +3 more sources

Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects

Pharmacology Research & Perspectives
Obesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti‐obesity pharmaceuticals has already demonstrated significant efficacy.
Igor Rubinić, Marija Kurtov, Robert Likić   +2 more
doaj   +1 more source